DOCSLIB.ORG

Copyrighted Material

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

127 Index Note: Page numbers in italic refer to figures, those in bold refer to tables. 7.1 see NG2 acute mixed phenotype with t(6;9) 52 α (alpha) 39 leukaemia see mixed with t(8;21)(q22;q22.1) 54, γ (gamma) 39 phenotype acute leukaemia 55, 93, 112 δ (delta) 39 acute monoblastic leukaemia, with t(9;11) or other KMT2A ε (epsilon) 39 case 102, 118–119 rearranged 52 κ (kappa) 38 acute monoblastic/monocytic acute promyelocytic leukaemia, λ (lambda) 38 leukaemia 33 with t(15;17)(q24.1;q21.2) μ (mu) 39 acute monocytic leukaemia, 48–52, 54, 93, 112 case 100, 116–118 acute undifferentiated a acute myeloid leukaemia leukaemia (AUL) 62 abbreviations ix–x, 47, 89 (AML) 48 case 108, 123 acute basophilic leukaemia associated with Down’s adult T‐cell leukaemia/ 14, 36, 55 syndrome 28, 55 lymphoma (ATLL) 74, acute lymphoblastic leukaemia with bi‐allelic CEBPA 92, 94, 112, 113 (ALL) 55–62, 90, 111 mutation 55 aggressive NK‐cell see also B‐lineage acute case 98, 115 leukaemia 76, 91, 111 lymphoblastic leukaemia immunophenotyping of alemtuzumab 27, 73 (B‐ALL) acute myeloid leukaemia ALK1 see CD246 case 103, 119–120 and blastic plasmacytoid ALK‐negative anaplastic large minimal residual disease dendritic cell cell lymphoma 75 (MRD) 77–78 neoplasm 53–54 ALK‐positive anaplastic large therapy‐related 103, 119–120 with inv(3) 52 cell lymphoma 75 T‐lineage acute lymphoblasticCOPYRIGHTED with inv(16) 12, 52, MATERIAL53 ALL see acute lymphoblastic leukaemia (T‐ALL) minimal residual disease leukaemia 60–62, 103–104, 119–120 (MRD) 78 AML see acute myeloid acute mast cell leukaemia with mutated NPM1 leukaemia 20, 23 92, 111 anaplastic large cell lymphoma acute megakaryoblastic with mutated RUNX1 55 75, 95, 113 leukaemia 15, 23, 25, 29, with myelodysplasia‐related case 105, 120 30, 53–54, 55 changes 55 angioimmunoblastic T‐cell with t(1;22)(p13.3;q13.1); not otherwise specified 55 lymphoma 74 RBM15‐MKL1 54, 93 with t(1;22) 92 annexin A1 39 Immunophenotyping for Haematologists: Principles and Practice, First Edition. Barbara J. Bain and Mike Leach. © 2021 John Wiley & Sons Ltd. Published 2021 by John Wiley & Sons Ltd. bindex.indd 127 01-09-2020 18:39:03 128 Index antigen expression during BCL6 39 CD4 13 maturation of the B‐ BCL10 39 CD5 13 lymphocyte lineage in the Bernard–Soulier syndrome CD7 13–14 bone marrow and in 6, 25 CD8 14 peripheral lymphoid blastic plasmacytoid dendritic CD9 14 tissues 51 cell neoplasm 65 CD10 14–15 antigen expression during case 101, 117 CD11a 15 maturation of the blinatumomab 12–13, 17 CD11b 15 erythroid lineage in the B‐lineage acute lymphoblastic CD11c 15 bone marrow 51 leukaemia (B‐ALL) CD13 15–16 antigen expression during 55–60, 90, 111 CD14 16 maturation of the monocyte BCR‐ABL1‐like 56, 57 CD15 16–17 lineage in the bone marrow with high hyperdiploidy 33, CD16 17 and, in tissues, to 55–57 CD19 17 macrophages 50 with t(1;19) 37, 59 CD19 expression, antigen expression during with t(4;11) 34, 57, 111 flow cytometric maturation of the with t(9;22) 57 immunophenotyping neutrophil lineage within with t(12;21) 57 3, 4, 5 the bone marrow 50 B‐lineage neoplasms, mature CD20 17–18 antigen expression during see mature B‐lineage CD21 18 maturation of the T‐ neoplasms CD22 18–19 lymphocyte lineage in the B‐lineage non‐Hodgkin CD23 19 bone marrow, thymus and lymphoma, minimal CD24 19 peripheral lymphoid residual disease CD25 19–20 tissues 52 (MRD) 78 CD26 20 atezolizumab 37 blood grouping 27 CD27 20 ATLL see adult T‐cell B lymphocyte 49, 51, 55, 56 CD28 21 leukaemia/lymphoma BOB.1 40 CD30 21 atypical chronic myeloid BRAFV600E 40 CD31 21–22 leukaemia 35, 63 brentuximab vedotin CD32 22 AUL see acute undifferentiated (auristatin) 21 CD33 22 leukaemia Burkitt lymphoma 69, 91, 111 CD34 22–23 auristatin (brentuximab CD34 expression, flow cytometric vedotin) 21 c immunophenotyping autoimmune calprotectin 40 3, 4–5 lymphoproliferative camidanlumab tesirine 20 CD35 23 syndrome 6, 28 camrelizumab 37 CD36 23 avelumab 37 carcinoembryonic antigen see CD37 23–24 axicabtagene ciloleucel 17 CD66a‐e CD38 24 carcinoma, metastatic 95, 113 CD40 24 b case 99, 115 CD41a 24–25 B‐ALL see B‐lineage acute CAR T cell see chimaeric CD41b 25 lymphoblastic leukaemia antigen receptor T cell CD42a 25 basiliximab 20 Castleman disease 21 CD42b 25 basogranulin 39 CD1 12 CD42c 25 basophil 42, 49 CD2 12 CD42d 25 BCL2 39 CD3 12–13 CD43 25–26 bindex.indd 128 01-09-2020 18:39:03 Index 129 CD44 26 CD203c 36 cluster of differentiation (CD) CD45 26 CD207 36 3, 7, 11 CD45 expression, CD227 36 CMML see chronic flow cytometric CD229 36 myelomonocytic leukaemia immunophenotyping 3–4 CD235a 36 cutaneous T‐cell lymphoma CD47 26–27 CD235b 36 23, 28, 35, 37 CD49b 27 CD236 36 cyclin D1 40 CD52 27 CD236R 36–37 cytokeratin 40 CD54 27 CD241 37 CD55 27 CD246 37 d CD56 27–28 CD269 37 dabrafenib 40 CD57 28–29 CD274 37 dacetuzumab 24 CD58 29 CD279 37 daclizumab 20 CD59 29 CD300e 37 daratumumab 24, 72 CD61 29 CD303 37 DBA.44 40 CD64 29–30 CD304 37–38 desmin 40 CD65 30 CD305 38 diffuse large B‐cell CD66a‐e 30 CD319 38 lymphoma 70 CD66e see CD66a‐e CD324 38 Down’s syndrome 15, 33, 53 CD68 30 CD326 38 acute myeloid leukaemia CD68R 30 CD335 38 (AML) 28, 55 CD71 30 CD340 38 transient abnormal CD79a 31 cemiplimab 37 myelopoiesis of Down’s CD79b 31 chimaeric antigen receptor T syndrome 15, 33, 53, 55, CD80 31 cell (CAR T cell) 12, 17, 96, 114 CD81 31 26, 34 durvalumab 37 CD86 31–32 chromogranin 40 CD94 32 chronic eosinophilic leukaemia e CD99 32 12, 19, 20 early T‐cell precursor acute CD103 32 chronic lymphocytic leukaemia lymphoblastic CD105 32 (CLL) 67 leukaemia 93 CD107a 32–33 case 93 early T‐cell precursor CD110 33 minimal residual disease lymphoblastic CD116 33 (MRD) 78 leukaemia 112 CD117 33 chronic lymphoproliferative E‐cadherin see CD324 CD123 33–34 disorder of NK cells 76 elotuzumab 38 CD127 34 chronic myeloid leukaemia, EMA see eosin‐5‐maleimide CD133 34 transformation, case endoglin see CD105 CD135 34 97, 114 endothelial cell 21 CD138 34 chronic myelomonocytic enteropathy‐associated T‐cell CD157 35 leukaemia (CMML) 13, lymphoma 21, 32, 75–76 CD158a‐k 35 16, 28, 62–64, 64 eosin‐5‐maleimide (EMA) 121 CD160 35 cirmtuzumab vedotin 44 eosinophil 49 CD161 35 classical Hodgkin lymphoma eosinophil major basic CD163 35 72, 73, 95, 113 protein 40 CD180 35–36 CLL see chronic lymphocytic eosinophil peroxidase 40 CD200 36 leukaemia Ep‐CAM see CD326 bindex.indd 129 01-09-2020 18:39:03 130 Index epithelial membrane antigen follicular T‐cell lymphoma 14 Hodgkin lymphoma see CD227 forward scatter (FSC), flow classical 72, 73, 95, 113 Erdheim–Chester disease cytometric nodular lymphocyte 40, 65 immunophenotyping predominant Hodgkin ERG 41 1–2, 3–5 lymphoma 72, 73 erythroblast 49 human T‐cell lymphotropic Ewing’s sarcoma 28, 32, 41 g virus 1 19–20 extranodal NK/T‐cell galiximab 31 lymphoma, nasal type 76 gemtuzumab ozogamicin 22 i genotype, immunophenotype ibalizumab 13 f correlation 48–55 ibritumomab tiuxetan 18 FLAER see fluorescent Glanzmann’s thrombasthenia immunoglobulin 41–42 aerolysin 6, 25, 27, 29 immunohistochemistry 7–8 FLI1 41 glycophorin see CD235a; immunophenotype, genotype flotetuzumab 34 CD235b; CD236; correlation 48–55 flow cytometric diagnosis, CD236R immunophenotype of cells of paroxysmal nocturnal glycosylphosphatidylinositol specific myeloid haemoglobinuria (GPI) 16, 78 lineages 48 78, 79 granzyme 41, 65, 75, 76 immunophenotyping of acute flow cytometric myeloid leukaemia and immunophenotyping h blastic plasmacytoid 1–7 haematogones, case dendritic cell CD19 expression 3, 4, 5 109–110, 124 neoplasm 53–54 CD34 expression 3, 4–5 haemophagocytic inotuzumab ozogamicin 18 CD45 expression 3–4 lymphohistiocytosis intestinal T‐cell lymphomas commonly used 7, 20 75–76 fluorochromes 2, 3 haemopoietic stem cell see also enteropathy‐ forward scatter (FSC) 24, 49, 122 associated T‐cell 1–2, 3–5 hairy cell leukaemia 68–69, lymphoma; monomorphic interpretation 8 93, 113 intestinal epitheliotropic limitations 8 minimal residual disease T‐cell lymphoma principles 2 (MRD) 78 intravascular large B‐cell problems and pitfalls 8 hairy cell leukaemia variant lymphoma 70 role 6–7 69, 91, 111 isatuximab 24 side scatter (SSC) 2, 3–5 hepatosplenic T‐cell fluorescent aerolysin lymphoma 74 k (FLAER) 41 HER2 see CD340 Ki‐67 42 paroxysmal nocturnal hereditary elliptocytosis, killer inhibitory receptor see haemoglobinuria case 119 CD158a‐k 78, 79, 122 hereditary spherocytosis, KIT see CD117 fluorochromes 1–3, 5–6, 7 case 106, 121 commonly used HHV8‐LANA1 41 l fluorochromes 2, 3 high‐grade B‐cell lymphoma Langerhans cell FMC7 41 with rearrangement of histiocytosis 65 follicular dendritic cells 12, MYC and BCL2, BCL6 or large granular lymphocytic 13, 17, 18, 19, 23, 24, 26, 35 both 70 leukaemia see T‐cell large follicular lymphoma 67–68, histiocytic sarcoma 66 granular lymphocytic 90, 111 HLA‐DR 41 leukaemia bindex.indd 130 01-09-2020 18:39:04 Index 131 LEF1 42 chronic lymphocytic characteristic light chain‐associated leukaemia (CLL) 67 immunophenotype of amyloidosis 72 diffuse large B‐cell mature T‐cell and NK‐cell lineage and stem cell lymphoma 70 neoplasms 73, 74 markers 49 follicular lymphoma chronic lymphoproliferative lintuzumab 22 67–68 disorder of NK cells 76 LL (lymphoblastic hairy cell leukaemia 68–69 extranodal NK/T‐cell lymphoma) 12 hairy cell leukaemia lymphoma, nasal type 76 LMP1 42 variant 69 hepatosplenic T‐cell loncastuximab 17 high‐grade B‐cell lymphoma lymphoma 74 lucatumumab 24 with rearrangement of intestinal T‐cell lymphomas lymphoblastic lymphoma MYC and BCL2, BCL6 or 75–76 (LL) 12 both 70 lymphomatoid
Recommended publications
  • Attachement B Summary

    Attachement B Summary

    Summary - Paediatric Strategy Forum Medicinal Product Development for Acute Myeloid Leukaemia in Children and Adolescents 24-6-19 Paediatric Strategy Forum for Medicinal Product Development for Acute Myeloid Leukaemia in Children and Adolescents ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration 11-12 April 2019 Summary Context: The fourth multi-stakeholder Paediatric Strategy Forum, organised by ACCELERATE in collaboration with the European Medicines Agency (EMA) with participation of the Food and Drug Administration (FDA) was held at Erasmus University, Rotterdam and focused on acute myeloid leukaemia (AML) in children and adolescents. Paediatric Strategy Forums are multi-stakeholder (clinicians, academics, patient advocates, pharmaceutical companies and regulators) scientific meetings on specific topics regarding paediatric oncology. The Forums aim to share information and advance learning, which may inform subsequent strategic and regulatory decisions on the development of medicines for children with cancer. The goal of this meeting was to facilitate development of innovative medicines for the treatment of children and adolescents with AML, and ultimately, by extension, introduce these medicines into the standard-of-care for children. The 5-year overall survival (OS) for paediatric AML currently is approximately 75%; however, the standard of care for frontline therapy for many decades has been daunorubicin and cytarabine. Furthermore, cardiotoxicity, due to anthracyclines, is an important long-term sequelae in a substantial proportion of survivors. AML is more frequent under the age of 3 years and its incidence initially declines and subsequently increases throughout young adulthood and is most frequent in the elderly. The occurrence of specific genetic alterations differs in AML in children compared to adults and the elderly.
  • Predictive QSAR Tools to Aid in Early Process Development of Monoclonal Antibodies

    Predictive QSAR Tools to Aid in Early Process Development of Monoclonal Antibodies

    Predictive QSAR tools to aid in early process development of monoclonal antibodies John Micael Andreas Karlberg Published work submitted to Newcastle University for the degree of Doctor of Philosophy in the School of Engineering November 2019 Abstract Monoclonal antibodies (mAbs) have become one of the fastest growing markets for diagnostic and therapeutic treatments over the last 30 years with a global sales revenue around $89 billion reported in 2017. A popular framework widely used in pharmaceutical industries for designing manufacturing processes for mAbs is Quality by Design (QbD) due to providing a structured and systematic approach in investigation and screening process parameters that might influence the product quality. However, due to the large number of product quality attributes (CQAs) and process parameters that exist in an mAb process platform, extensive investigation is needed to characterise their impact on the product quality which makes the process development costly and time consuming. There is thus an urgent need for methods and tools that can be used for early risk-based selection of critical product properties and process factors to reduce the number of potential factors that have to be investigated, thereby aiding in speeding up the process development and reduce costs. In this study, a framework for predictive model development based on Quantitative Structure- Activity Relationship (QSAR) modelling was developed to link structural features and properties of mAbs to Hydrophobic Interaction Chromatography (HIC) retention times and expressed mAb yield from HEK cells. Model development was based on a structured approach for incremental model refinement and evaluation that aided in increasing model performance until becoming acceptable in accordance to the OECD guidelines for QSAR models.
  • Comparative Safety and Efficacy of Anti-PD-1 Monotherapy, Chemotherapy

    Comparative Safety and Efficacy of Anti-PD-1 Monotherapy, Chemotherapy

    Lv et al. Journal for ImmunoTherapy of Cancer (2019) 7:159 https://doi.org/10.1186/s40425-019-0636-7 COMMENTARY Open Access Comparative safety and efficacy of anti-PD- 1 monotherapy, chemotherapy alone, and their combination therapy in advanced nasopharyngeal carcinoma: findings from recent advances in landmark trials Jia-Wei Lv1†, Jun-Yan Li1†, Lin-Na Luo2†, Zi-Xian Wang2* and Yu-Pei Chen1* Abstract Recent phase 1–2 trials reported manageable safety profiles and promising antitumor activities of anti-PD-1 drugs (pembrolizumab, nivolumab, camrelizumab and JS001) with/without chemotherapy in recurrent/metastatic nasopharyngeal carcinoma (RM-NPC), however head-to-head comparison among these regimens is lacking. We aimed to comprehensively compare the efficacy and safety of different anti-PD-1 drugs, standard chemotherapy, and their combination therapy in RM-NPC. Adverse event (AE) and objective response rate (ORR) were assessed. The pooled incidence rates of grade 1–5/3–5 AEs were 74.1%/29.6, 54.2%/17.4, 92.3%/24.5, 96.8%/16.1, 91.2%/42.8, and 100%/87.9% for pembrolizumab, nivolumab, JS001, camrelizumab, chemotherapy and camrelizumab+chemotherapy, respectively, which suggested that nivolumab and pembrolizumab exhibited the optimal safety regarding grade 1–5 AEs whereas camrelizumab and nivolumab regarding grade 3–5 AEs. As second- or later-line therapy, ORR was higher with camrelizumab (34.1%), followed by pembrolizumab (26.3%), JS001 (23.3%), and nivolumab (19.0%); whereas ORR with first-line nivolumab reached 40%. Additionally, first-line camrelizumab+chemotherapy achieved a dramatically higher ORR than that with chemotherapy alone (90.9% vs.
  • 2015 Post-ASH Report

    2015 Post-ASH Report

    Datamonitor Healthcare Trialtrove Biomedtracker Pharma intelligence | Pharma intelligence | Pharma intelligence | 2015 Post-ASH Report RACHEL MEIGHAN-MANTHA Principal Analyst, Citeline JOSEPH HEDDEN Senior Analyst, Datamonitor Healthcare Summary Profiled themes at the 57th Annual Meeting and Exposition of the American Society of Hematology (ASH), held December 5-8, 2015, in Orlando, Florida, included Genomic Profiling and Chemical Biology, Genome Editing and Gene Therapy, Epigenetic Mechanisms, Immunologic Treatments, Stem Cell Biology and Regenerative Medicine and Preventing Venous Thromboembolic Disease. This report will mainly focus on the theme of Immunologic Treatments because of the importance and popularity of immunotherapies for many different hematological cancers. Also covered in this report are the results from pivotal trials presented at ASH, as well as highlights from other drugs/therapies of interest. In addition, we felt it was important to cover first-in-human trials since (hopefully) some of these drugs/therapies will be in pivotal trials in a few years. At the end of the report, we’ve included a section showcasing drugs that had top- line results presented at ASH, followed by a list of other data presentations supplied by BioMedTracker (BMT). Accompanying links to BioMedTracker events along with changes to the drugs’ likelihood of approval (LOA) are also provided throughout the report. Finally, additional supplemental material related to ASH is listed in the Appendix. 2 Datamonitor Healthcare Trialtrove Biomedtracker
  • Tanibirumab (CUI C3490677) Add to Cart

    Tanibirumab (CUI C3490677) Add to Cart

    5/17/2018 NCI Metathesaurus Contains Exact Match Begins With Name Code Property Relationship Source ALL Advanced Search NCIm Version: 201706 Version 2.8 (using LexEVS 6.5) Home | NCIt Hierarchy | Sources | Help Suggest changes to this concept Tanibirumab (CUI C3490677) Add to Cart Table of Contents Terms & Properties Synonym Details Relationships By Source Terms & Properties Concept Unique Identifier (CUI): C3490677 NCI Thesaurus Code: C102877 (see NCI Thesaurus info) Semantic Type: Immunologic Factor Semantic Type: Amino Acid, Peptide, or Protein Semantic Type: Pharmacologic Substance NCIt Definition: A fully human monoclonal antibody targeting the vascular endothelial growth factor receptor 2 (VEGFR2), with potential antiangiogenic activity. Upon administration, tanibirumab specifically binds to VEGFR2, thereby preventing the binding of its ligand VEGF. This may result in the inhibition of tumor angiogenesis and a decrease in tumor nutrient supply. VEGFR2 is a pro-angiogenic growth factor receptor tyrosine kinase expressed by endothelial cells, while VEGF is overexpressed in many tumors and is correlated to tumor progression. PDQ Definition: A fully human monoclonal antibody targeting the vascular endothelial growth factor receptor 2 (VEGFR2), with potential antiangiogenic activity. Upon administration, tanibirumab specifically binds to VEGFR2, thereby preventing the binding of its ligand VEGF. This may result in the inhibition of tumor angiogenesis and a decrease in tumor nutrient supply. VEGFR2 is a pro-angiogenic growth factor receptor
  • Engineered Technologies and Bioanalysis of Multispecific Antibody Formats

    Engineered Technologies and Bioanalysis of Multispecific Antibody Formats

    Journal of Applied Bioanalysis openaccess http://dx.doi.org/10.17145/jab.20.005 REVIEW Engineered Technologies and Bioanalysis of multispecific Antibody Formats Marta Amaral, Soraya Hölper, Christian Lange, Jennifer Jung, Hanno Sjuts, Sandra Weil, Melanie Fischer, Katarina Rado�evi�, Ercole Rao* Sanofi R&D, Biologics Research. *Correspondence: Sanofi-Aventis Deutschland GmbH, R&D, Biologics Research, Industriepark Höchst, H812, 65926 Frankfurt am Main, Germany. Phone: +49 6930515147. Email: [email protected] Citation: Amaral M, Hölper S, Lange C, Jung J, Sjuts H, Weil S, Fischer M, Rado�evic K, Rao E. Engineered Technologies and Bioanalysis of multispecific ABSTRACT antibody formats. J Appl Bioanal 6(1), The idea of designing multispecific antibodies capable of simultaneously 26-51 (2020). engaging two or more epitopes on the same or different antigens was developed more than 50 years ago. However, the molecular complexity of such Editor: molecules may pose significant challenges for their development and clinical Dr. Lin-zhi Chen, Boehringer use. Particularly challenging is to obtain the correctly assembled combination of Ingelheim Pharmaceuticals Inc., different polypeptide chains, which places significant demand on downstream Ridgefield, CT 06877, USA. process development, analytical characterization and control strategy. Here, we review the progress made in protein engineering to force the correct assembly of Received: July 29, 2019. different heavy and light chains, as well as upstream and downstream processes Revised: September 13, 2019. currently applied to control generation of unwanted byproduct species. We Accepted: September 16, 2019. cover in-depth the analytical methods available to characterize such complex molecules, focusing on mispairing analysis and functional characterization.
  • 2017 Immuno-Oncology Medicines in Development

    2017 Immuno-Oncology Medicines in Development

    2017 Immuno-Oncology Medicines in Development Adoptive Cell Therapies Drug Name Organization Indication Development Phase ACTR087 + rituximab Unum Therapeutics B-cell lymphoma Phase I (antibody-coupled T-cell receptor Cambridge, MA www.unumrx.com immunotherapy + rituximab) AFP TCR Adaptimmune liver Phase I (T-cell receptor cell therapy) Philadelphia, PA www.adaptimmune.com anti-BCMA CAR-T cell therapy Juno Therapeutics multiple myeloma Phase I Seattle, WA www.junotherapeutics.com Memorial Sloan Kettering New York, NY anti-CD19 "armored" CAR-T Juno Therapeutics recurrent/relapsed chronic Phase I cell therapy Seattle, WA lymphocytic leukemia (CLL) www.junotherapeutics.com Memorial Sloan Kettering New York, NY anti-CD19 CAR-T cell therapy Intrexon B-cell malignancies Phase I Germantown, MD www.dna.com ZIOPHARM Oncology www.ziopharm.com Boston, MA anti-CD19 CAR-T cell therapy Kite Pharma hematological malignancies Phase I (second generation) Santa Monica, CA www.kitepharma.com National Cancer Institute Bethesda, MD Medicines in Development: Immuno-Oncology 1 Adoptive Cell Therapies Drug Name Organization Indication Development Phase anti-CEA CAR-T therapy Sorrento Therapeutics liver metastases Phase I San Diego, CA www.sorrentotherapeutics.com TNK Therapeutics San Diego, CA anti-PSMA CAR-T cell therapy TNK Therapeutics cancer Phase I San Diego, CA www.sorrentotherapeutics.com Sorrento Therapeutics San Diego, CA ATA520 Atara Biotherapeutics multiple myeloma, Phase I (WT1-specific T lymphocyte South San Francisco, CA plasma cell leukemia www.atarabio.com
  • Looking for Therapeutic Antibodies in Next Generation Sequencing Repositories

    Looking for Therapeutic Antibodies in Next Generation Sequencing Repositories

    bioRxiv preprint doi: https://doi.org/10.1101/572958; this version posted March 10, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license. Title: Looking for Therapeutic Antibodies in Next Generation Sequencing Repositories. Authors: Konrad Krawczyk1*, Matthew Raybould2, Aleksandr Kovaltsuk2, Charlotte M. Deane2 1 NaturalAntibody, Hamburg, Germany 2 Oxford University Department of Statistics, Oxford, UK *Correspondence to [email protected] Abstract: Recently it has become possible to query the great diversity of natural antibody repertoires using Next Generation Sequencing (NGS). These methods are capable of producing millions of sequences in a single experiment. Here we compare Clinical Stage Therapeutic antibodies to the ~1b sequences from 60 independent sequencing studies in the Observed Antibody Space Database. Of the 242 post Phase I antibodies, we find 16 with sequence identity matches of 95% or better for both heavy and light chains. There are also 54 perfect matches to therapeutic CDR-H3 regions in the NGS outputs, suggesting a nontrivial amount of convergence between naturally observed sequences and those developed artificially. This has potential implications for both the discovery of antibody therapeutics and the legal protection of commercial antibodies. Introduction Antibodies are proteins in jawed vertebrates that recognize noxious molecules (antigens) for elimination. An organism expresses millions of diverse antibodies to increase the chances that some of them will be able to bind the foreign antigen, initiating the adaptive immune response.
  • Antibodies to Watch in 2021 Hélène Kaplona and Janice M

    Antibodies to Watch in 2021 Hélène Kaplona and Janice M

    MABS 2021, VOL. 13, NO. 1, e1860476 (34 pages) https://doi.org/10.1080/19420862.2020.1860476 PERSPECTIVE Antibodies to watch in 2021 Hélène Kaplona and Janice M. Reichert b aInstitut De Recherches Internationales Servier, Translational Medicine Department, Suresnes, France; bThe Antibody Society, Inc., Framingham, MA, USA ABSTRACT ARTICLE HISTORY In this 12th annual installment of the Antibodies to Watch article series, we discuss key events in antibody Received 1 December 2020 therapeutics development that occurred in 2020 and forecast events that might occur in 2021. The Accepted 1 December 2020 coronavirus disease 2019 (COVID-19) pandemic posed an array of challenges and opportunities to the KEYWORDS healthcare system in 2020, and it will continue to do so in 2021. Remarkably, by late November 2020, two Antibody therapeutics; anti-SARS-CoV antibody products, bamlanivimab and the casirivimab and imdevimab cocktail, were cancer; COVID-19; Food and authorized for emergency use by the US Food and Drug Administration (FDA) and the repurposed Drug Administration; antibodies levilimab and itolizumab had been registered for emergency use as treatments for COVID-19 European Medicines Agency; in Russia and India, respectively. Despite the pandemic, 10 antibody therapeutics had been granted the immune-mediated disorders; first approval in the US or EU in 2020, as of November, and 2 more (tanezumab and margetuximab) may Sars-CoV-2 be granted approvals in December 2020.* In addition, prolgolimab and olokizumab had been granted first approvals in Russia and cetuximab saratolacan sodium was first approved in Japan. The number of approvals in 2021 may set a record, as marketing applications for 16 investigational antibody therapeutics are already undergoing regulatory review by either the FDA or the European Medicines Agency.
  • W W W .Bio Visio N .Co M

    W W W .Bio Visio N .Co M

    Biosimilar Monoclonal Antibodies Human IgG based monoclonal antibodies (mAbs) are the fastest-growing category of therapeutics for cancer therapy. Several mechanisms of tumor cell killing by antibodies (mAbs) can be summarized as: direct action through receptor blockade or induction of apoptosis; immune-mediated cell killing by complement-dependent cytotoxicity (CDC), antibody-dependent cellular cytotoxicity (ADCC) or regulation of T cell function. Several monoclonal antibodies have received FDA approval for the treatment of a variety of solid tumors and hematological malignancies. BioVision is pleased to offer research grade biosimilars in human IgG format for your research needs. Our monoclonal antibodies are manufactured using recombinant technology with variable regions from the therapeutic antibody to achieve similar safety and efficacy. These antibodies can be used as controls for preclinical lead identification and potency assays for the development of novel therapeutics. Antibody Name Cat. No. Trade Name Isotype Size Anti-alpha 5 beta 1 Integrin (Volociximab), Human IgG4 Ab A1092 - IgG4 200 µg Anti-Beta-galactosidase, Human IgG1 Ab A1104 - IgG1 200 µg Anti-C5 (Eculizumab), Humanized Ab A2138 - IgG2/4 100 μg Anti-Carcinoembryonic antigen (Arcitumomab), Human IgG1 Ab A1096 - IgG1 200 µg Anti-CCR4 (Mogamulizumab), Human IgG1, kappa Ab A2005 - IgG1 200 μg Anti-CD11a (Efalizumab), Human IgG1 Ab A1089 Raptiva IgG1 200 µg Anti-CD20 (Rituximab), Chimeric Ab A1049 Mabthera IgG1 100 µg Anti-CD22 (Epratuzumab), Human IgG1 Ab A1445 LymphoCide IgG1 200 µg Anti-CD3 epsilon (Muromonab), Mouse IgG2a, kappa Ab A2008 - IgG2a 200 μg Anti-CD33 (Gemtuzumab), Human IgG4 Ab A1443 Mylotarg IgG4 200 µg Anti-CD38 (Daratumumab), Human IgG1 Ab A2151 Darzalex IgG1 100 μg www.biovision.com 155 S.
  • Flotetuzumab: CD123 × CD3 DART Molecule

    Flotetuzumab: CD123 × CD3 DART Molecule

    ® Breakthrough Biologics, Life-changing Medicines Corporate Update January 6, 2019 Legal Notices The information in this slide deck is current as of January 6, 2019, unless otherwise noted. The information in this slide deck is qualified in its entirety by reference to MacroGenics’ Annual, Quarterly and Current Reports filed with the SEC. MacroGenics undertakes no obligation to update any of the information herein. Cautionary Note on Forward-Looking Statements Any statements in these materials about future expectations, plans and prospects for MacroGenics (“Company”), including statements about the Company’s strategy, future operations, clinical development of the Company’s therapeutic candidates, milestone or opt-in payments from the Company’s collaborators, the Company’s anticipated milestones and future expectations and plans and prospects for the Company and other statements containing the words “subject to”, "believe", “anticipate”, “plan”, “expect”, “intend”, “estimate”, “project”, “may”, “will”, “should”, “would”, “could”, “can”, the negatives thereof, variations thereon and similar expressions, or by discussions of strategy constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the uncertainties inherent in the initiation and enrollment of future clinical trials, expectations of expanding ongoing clinical trials, availability and timing of data from ongoing clinical trials, expectations for regulatory approvals, other matters that could affect the availability or commercial potential of the Company's product candidates and other risks described in the Company’s filings with the Securities and Exchange Commission.
  • Immune Checkpoint Blockade Therapies for HCC: Current Status and Future Implications

    Immune Checkpoint Blockade Therapies for HCC: Current Status and Future Implications

    Shrestha et al. Hepatoma Res 2019;5:32 Hepatoma Research DOI: 10.20517/2394-5079.2019.24 Review Open Access Immune checkpoint blockade therapies for HCC: current status and future implications Ritu Shrestha1,2, Kim R. Bridle1,2, Darrell H. G. Crawford1,2, Aparna Jayachandran1,2 1The University of Queensland, Faculty of Medicine, Brisbane, Queensland 4120, Australia. 2Gallipoli Medical Research Institute, Greenslopes Private Hospital, Brisbane, Queensland 4120, Australia. Correspondence to: Dr. Aparna Jayachandran, The University of Queensland, Faculty of Medicine, Lower Lobby Level, Administration Building, Greenslopes Private Hospital, Greenslopes, Queensland 4120, Australia. E-mail: [email protected] How to cite this article: Shrestha R, Bridle KR, Crawford DHG, Jayachandran A. Immune checkpoint blockade therapies for HCC: current status and future implications. Hepatoma Res 2019;5:32. http://dx.doi.org/10.20517/2394-5079.2019.24 Received: 27 Jun 2019 First Decision: 11 Jul 2019 Revised: 6 Aug 2019 Accepted: 9 Aug 2019 Published: 3 Sep 2019 Science Editors: Jia Fan, Ying-Hong Shi Copy Editor: Jia-Jia Meng Production Editor: Jing Yu Abstract Received: First Decision: Revised: Accepted: Published: Hepatocellular carcinoma (HCC) is the most lethal and common type of liver cancer with limited treatment options Science Editor: Copy Editor: Production Editor: Jing Yu at the advanced stage. The use of immune checkpoint inhibitor (ICI) based immunotherapy is exponentially increasing in the treatment of patients with advanced solid tumors. The expression of immune checkpoints on tumor cells leading to lower activity of T-cells is one of the major mechanisms of immune escape. Checkpoint blockade immunotherapies with antibodies against PD-1, PD-L1 or CTLA-4 are being investigated in clinical trials in HCC patients.